CDT
NASDAQ HealthcareCDT Equity Inc. - Common Stock
Biotechnology
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company's pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto's thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It also provides treatments for inflammatory disorders, oncology, dermatology, rare diseases and animal health. The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025. The company was founded in 2019 and is based in Naples, Florida.
๐ Market Data
| Price | $0.17 |
|---|---|
| Volume | 17,420,300 |
| Market Cap | 2.38M |
| Beta | 1.450 |
| 200-Day MA | $122.44 |
| 50-Day MA | $2.37 |
| 52-Week High | $1778.00 |
| 52-Week Low | $0.16 |
๐ฏ Investment Strategy Scores
CDT scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ช Falling Knife (99/100) โ this strategy Contrarian plays (oversold + below moving average).
Lowest fit among scored strategies: ๐ฐ Dividend Daddy (15/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find CDT in your text
Paste any article, transcript, or post โ the tool will extract CDT and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-09-18.